{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:11:12Z","timestamp":1790824272675,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.009","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T02:00:46Z","timestamp":1704506446000},"page":"477-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Measurable Residual Disease and Decision-Making in Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.hoc.2023.12.009_bib1","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.009_bib2","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib3","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.009_bib4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.12.009_bib5","first-page":"1","article-title":"Minimal residual disease analysis in myeloma \u2013 when, why and where","author":"Yanamandra","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2023.12.009_bib6","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","author":"Costa","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"key":"10.1016\/j.hoc.2023.12.009_bib7","unstructured":"Adaptive Biotechnologies Corporation. clonoSEQ Assay Technical Information. Available at: https:\/\/www.clonoseq.com\/sites\/default\/files\/clonoSEQ_TechnicalInformationSummary_21Sept2018.pdf. Accessed February 10, 2020."},{"issue":"14","key":"10.1016\/j.hoc.2023.12.009_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2023.12.009_bib9","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2023.12.009_bib10","first-page":"435","article-title":"Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.009_bib11","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.009_bib12","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.009_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.009_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2021.280051","article-title":"Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study","volume":"108","author":"Kraeber-Bod\u00e9r\u00e9","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib15","first-page":"1","article-title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.009_bib17","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.009_bib18","first-page":"8012","article-title":"Prospective comparison of whole body MRI and FDG PET\/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial","volume":"39","author":"Kaiser","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.009_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"27","key":"10.1016\/j.hoc.2023.12.009_bib20","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.009_bib21","first-page":"1383","article-title":"More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia\u2013Like Multiple Myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"27","key":"10.1016\/j.hoc.2023.12.009_bib22","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.009_bib23","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib24","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2022-167382","article-title":"Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow","volume":"140","author":"Notarfranchi","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.009_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.009_bib26","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Advances"},{"key":"10.1016\/j.hoc.2023.12.009_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.786451","article-title":"Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse","volume":"12","author":"Dhakal","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry","volume":"62","author":"Kohlhagen","year":"2016","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.009_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.009_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib37","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1182\/blood-2022-160249","article-title":"Comparison of the Analytical Performance of EXENT\u00ae, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.009_bib38","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/rcm.7314","article-title":"Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine","volume":"29","author":"Barnidge","year":"2015","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.009_bib39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib40","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2022-165441","article-title":"Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial","volume":"140","author":"Puig","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.009_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2021-151557","article-title":"Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial","volume":"138","author":"Puig","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.009_bib43","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease\u2013Adapted Study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.009_bib44","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A\u00a0Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.009_bib45","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","article-title":"Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients","volume":"20","author":"McDonald","year":"2021","journal-title":"J\u00a0Proteome Res"},{"issue":"S2","key":"10.1016\/j.hoc.2023.12.009_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.HS9.0000936168.61107.6f","article-title":"P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT)","volume":"7","author":"Bonifay","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib47","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1182\/blood-2022-155582","article-title":"Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma","volume":"140","author":"Slade","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.hoc.2023.12.009_bib49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ifacol.2015.10.123","volume":"48","author":"Kendrick","year":"2015","journal-title":"IFAC-PapersOnLine"},{"key":"10.1016\/j.hoc.2023.12.009_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphys.2017.00149","article-title":"Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma","volume":"8","author":"Kendrick","year":"2017","journal-title":"Front Physiol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib51","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.009_bib52","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.hoc.2023.12.009_bib53","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.009_bib54","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2015-04-638742","article-title":"Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality","volume":"126","author":"Mart\u00ednez-L\u00f3pez","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.009_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237155","article-title":"The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements","volume":"15","author":"Cedena","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2023.12.009_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012319","article-title":"Validation of the IMWG standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change?","author":"Jim\u00e9nez Ubieto","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.009_bib58","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.009_bib60","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.hoc.2023.12.009_bib61","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","author":"Martin","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.009_bib62","first-page":"8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.009_bib63","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.009_bib64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib65","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and\/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.009_bib66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.009_bib67","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.009_bib68","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.009_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib71","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2022-158643","article-title":"Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)","volume":"140","author":"Derman","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.009_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702\/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-022-01779-8","article-title":"Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment","volume":"37","author":"Claveau","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.009_bib75","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.18568","article-title":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","volume":"200","author":"Etekal","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib76","doi-asserted-by":"crossref","first-page":"kz002","DOI":"10.1093\/jncics\/pkz002","article-title":"A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.hoc.2023.12.009_bib77","first-page":"1","article-title":"Impact of treatment effect on MRD and PFS: an aggregate analysis from randomized clinical trials in multiple myeloma","author":"Paiva","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.009_bib78","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.009_bib79","unstructured":"Research C for DE and. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment. U.S. Food and Drug Administration. Published January 24, 2020. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and. Accessed June 30, 2023."},{"issue":"6","key":"10.1016\/j.hoc.2023.12.009_bib80","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V18.6.202166","article-title":"Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma","volume":"18","author":"Dhakal","year":"2021","journal-title":"The Hematologist"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.009_bib82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.12.009_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18948","article-title":"Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma","author":"Correia","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.009_bib84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-022-00705-6","article-title":"Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma","volume":"12","author":"Derman","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.009_bib85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","article-title":"Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma","volume":"14","author":"Martinez-Lopez","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.009_bib86","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2021-151832","article-title":"A\u00a0Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma","volume":"138","author":"Derman","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.009_bib87","first-page":"2889","article-title":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.009_bib88","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","article-title":"Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma","volume":"4","author":"Alonso","year":"2020","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.009_bib89","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2023.12.009_bib90","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","author":"Paiva","year":"2019","journal-title":"J\u00a0Clin Orthod"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:20:11Z","timestamp":1760592011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001764"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable Residual Disease and Decision-Making in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}